Index - P/E 118.42 EPS (ttm) 0.14 Insider Own 46.38% Shs Outstand 282.83M Perf Week -1.25%
Market Cap 4.70B Forward P/E 19.90 EPS next Y 0.83 Insider Trans -23.34% Shs Float 151.87M Perf Month 8.01%
Income 39.86M PEG 9.95 EPS next Q 0.18 Inst Own 47.42% Short Float 7.01% Perf Quarter 38.13%
Sales 1.10B P/S 4.28 EPS this Y -10.65% Inst Trans -1.22% Short Ratio 8.27 Perf Half Y 43.76%
Book/sh 1.49 P/B 11.11 EPS next Y 15.20% ROA 1.30% Short Interest 10.65M Perf Year 8.36%
Cash/sh 0.87 P/C 18.96 EPS next 5Y 11.90% ROE 9.48% 52W Range 10.71 - 17.44 Perf YTD -1.54%
Dividend Est. - P/FCF 4121.45 EPS past 5Y - ROI 1.45% 52W High -4.87% Beta 2.07
Dividend TTM - Quick Ratio 2.57 Sales past 5Y 7.12% Gross Margin 49.48% 52W Low 54.90% ATR (14) 0.54
Dividend Ex-Date - Current Ratio 2.93 EPS Y/Y TTM 114.81% Oper. Margin 33.28% RSI (14) 60.60 Volatility 2.43% 3.53%
Employees 3000 Debt/Eq 5.55 Sales Y/Y TTM 12.50% Profit Margin 3.63% Recom 1.88 Target Price 16.36
Option/Short Yes / Yes LT Debt/Eq 5.51 EPS Q/Q -62.83% Payout 0.00% Rel Volume 0.25 Prev Close 16.55
Sales Surprise 3.81% EPS Surprise 15.36% Sales Q/Q 8.35% Earnings Aug 05 BMO Avg Volume 1.29M Price 16.59
SMA20 3.63% SMA50 12.69% SMA200 21.02% Trades
Volume 278,175 Change 0.24%
Date
Action
Analyst
Rating Change
Price Target Change
May-21-24 Initiated Piper Sandler
Neutral
$13
Apr-03-24 Upgrade Citigroup
Neutral → Buy
$18 → $16
Mar-25-24 Upgrade Jefferies
Hold → Buy
$15 → $15.50
Feb-06-24 Resumed KeyBanc Capital Markets
Sector Weight
Jun-26-23 Upgrade KeyBanc Capital Markets
Sector Weight → Overweight
$24
Jan-23-23 Upgrade JP Morgan
Underweight → Neutral
$6 → $18
Jan-11-23 Upgrade Wolfe Research
Peer Perform → Outperform
$25
Jan-11-23 Upgrade Barclays
Underweight → Overweight
$6 → $22
Nov-15-22 Downgrade Barclays
Equal Weight → Underweight
$6
Oct-05-22 Downgrade Citigroup
Buy → Neutral
$25 → $9
Sep-26-22 Downgrade KeyBanc Capital Markets
Overweight → Sector Weight
Sep-21-22 Downgrade JP Morgan
Overweight → Underweight
$26 → $9
Sep-20-22 Downgrade Goldman
Buy → Neutral
$9
Jun-09-22 Downgrade Wolfe Research
Outperform → Peer Perform
$26
Apr-06-22 Initiated Wolfe Research
Outperform
$26
Mar-03-22 Downgrade Jefferies
Buy → Hold
$34 → $22
Mar-02-22 Downgrade Barclays
Overweight → Equal Weight
$24
Mar-03-21 Initiated Barclays
Overweight
$35
Jan-14-21 Initiated Robert W. Baird
Outperform
$31
Dec-15-20 Initiated RBC Capital Mkts
Outperform
$31
Show Previous Ratings
Sep-14-24 01:53AM
Sep-10-24 03:16PM
(Investor's Business Daily)
Sep-04-24 04:41PM
Aug-05-24 11:10PM
(Thomson Reuters StreetEvents) +7.56%
04:00PM
09:30AM
Loading…
09:30AM
08:15AM
07:28AM
07:00AM
Aug-01-24 07:00AM
Jul-22-24 05:00PM
Jun-26-24 06:33AM
May-30-24 05:12PM
May-21-24 09:32AM
08:06AM
07:42AM
Loading…
07:42AM
May-04-24 09:28AM
May-03-24 03:32AM
May-02-24 10:00PM
11:56AM
11:54AM
08:37AM
08:35AM
07:00AM
Apr-25-24 10:01AM
Apr-11-24 04:00PM
Mar-18-24 08:28AM
Mar-06-24 01:00PM
Mar-05-24 10:28AM
Feb-28-24 06:40PM
11:11PM
Loading…
Feb-27-24 11:11PM
(Thomson Reuters StreetEvents)
05:30PM
01:45PM
09:30AM
08:25AM
07:33AM
07:00AM
Feb-22-24 09:15AM
Feb-20-24 10:00AM
Feb-15-24 07:00AM
Jan-30-24 06:17AM
Jan-09-24 07:00AM
Jan-03-24 07:00AM
Dec-06-23 11:54AM
Nov-24-23 02:19PM
Nov-13-23 07:00AM
Nov-05-23 12:42PM
Nov-01-23 10:31PM
(Thomson Reuters StreetEvents)
01:00PM
09:15AM
07:00AM
Oct-18-23 07:00AM
Aug-07-23 01:19PM
Aug-03-23 01:00PM
09:30AM
08:55AM
07:00AM
Jul-18-23 07:00AM
Jul-03-23 07:11AM
Jun-26-23 07:00AM
Jun-23-23 07:12AM
Jun-22-23 05:58PM
02:22PM
08:20AM
Jun-21-23 08:00PM
May-30-23 05:49AM
May-12-23 04:30PM
May-05-23 01:49PM
May-03-23 10:27PM
(Thomson Reuters StreetEvents) -5.10%
02:00PM
08:45AM
07:00AM
Apr-26-23 08:00PM
Apr-18-23 08:00AM
Mar-21-23 04:30PM
Mar-06-23 01:05AM
Mar-01-23 05:50AM
03:38AM
(Thomson Reuters StreetEvents)
Feb-28-23 02:00PM
08:45AM
07:00AM
Feb-23-23 05:20PM
07:35AM
Feb-15-23 08:00AM
Feb-13-23 07:15AM
Jan-23-23 09:48AM
Jan-14-23 07:00AM
Jan-10-23 05:34PM
03:44PM
11:50AM
07:42AM
Jan-09-23 06:54PM
05:31PM
Jan-06-23 07:28AM
Jan-03-23 04:30PM
Dec-16-22 02:30PM
Dec-08-22 02:13PM
Nov-26-22 07:56AM
Nov-21-22 05:00PM
04:29PM
Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. The firm operates through the following businesses: Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets by using following technologies: gamma irradiation, EO processing and E-beam irradiation. The Nordion business provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was founded in 1978 and is headquartered in Broadview Heights, OH.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
WARBURG PINCUS & CO. Director Sep 06 '24 Sale 15.03 15,000,000 225,450,000 73,822,952 Sep 09 07:13 PM WARBURG PINCUS & CO. Director Sep 06 '24 Sale 15.03 15,000,000 225,450,000 73,822,952 Sep 09 07:13 PM GTCR INVESTMENT XI LLC Director Sep 06 '24 Sale 15.03 10,000,000 150,300,000 49,215,301 Sep 09 05:36 PM WARBURG PINCUS & CO. Director Mar 04 '24 Sale 14.31 16,594,363 237,423,849 88,822,952 Mar 06 05:39 PM WARBURG PINCUS & CO. Director Mar 04 '24 Sale 14.31 16,594,363 237,423,849 88,822,952 Mar 06 05:38 PM GTCR INVESTMENT XI LLC Director Mar 04 '24 Sale 14.31 11,062,908 158,282,556 59,215,301 Mar 06 05:35 PM Klee Ann R. Director Mar 04 '24 Sale 14.31 5,750 82,268 86,735 Mar 06 04:41 PM Rutz Michael P President of Sterigenics Mar 04 '24 Sale 14.31 83,109 1,189,082 544,409 Mar 05 06:06 PM Petras Michael B. Jr. Chairman & CEO Mar 04 '24 Sale 14.31 1,003,870 14,362,870 5,453,580 Mar 05 05:35 PM
Index RUT P/E - EPS (ttm) -1.00 Insider Own 16.98% Shs Outstand 132.23M Perf Week -1.69%
Market Cap 1.17B Forward P/E 424.27 EPS next Y 0.02 Insider Trans -29.26% Shs Float 117.52M Perf Month -6.06%
Income -132.08M PEG - EPS next Q -0.01 Inst Own 89.99% Short Float 7.13% Perf Quarter 13.92%
Sales 278.58M P/S 4.19 EPS this Y -211.42% Inst Trans -0.47% Short Ratio 3.53 Perf Half Y 1.08%
Book/sh 3.09 P/B 2.67 EPS next Y 158.16% ROA -7.12% Short Interest 8.38M Perf Year -17.60%
Cash/sh 4.05 P/C 2.04 EPS next 5Y - ROE -27.59% 52W Range 4.52 - 11.56 Perf YTD 25.92%
Dividend Est. - P/FCF - EPS past 5Y -37.53% ROI -13.40% 52W High -28.62% Beta 0.01
Dividend TTM - Quick Ratio 9.28 Sales past 5Y 47.72% Gross Margin 41.33% 52W Low 82.47% ATR (14) 0.59
Dividend Ex-Date - Current Ratio 10.00 EPS Y/Y TTM -273.90% Oper. Margin -13.85% RSI (14) 42.54 Volatility 7.04% 5.76%
Employees 650 Debt/Eq 1.29 Sales Y/Y TTM -48.78% Profit Margin -47.41% Recom 1.60 Target Price 11.09
Option/Short Yes / Yes LT Debt/Eq 1.26 EPS Q/Q -12.50% Payout - Rel Volume 0.97 Prev Close 8.84
Sales Surprise 2.06% EPS Surprise -100.00% Sales Q/Q 6.51% Earnings Aug 07 AMC Avg Volume 2.37M Price 8.25
SMA20 -7.14% SMA50 -7.21% SMA200 5.35% Trades
Volume 2,014,000 Change -6.70%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-28-24 Initiated Wells Fargo
Overweight
$10
Aug-13-24 Downgrade Morgan Stanley
Overweight → Equal-Weight
$11 → $10
Apr-10-24 Initiated Craig Hallum
Buy
$15
Dec-12-23 Upgrade BofA Securities
Neutral → Buy
$10 → $8
Aug-08-23 Downgrade KeyBanc Capital Markets
Overweight → Sector Weight
May-23-23 Downgrade Credit Suisse
Outperform → Neutral
$18 → $14
May-09-23 Downgrade Goldman
Buy → Neutral
Jan-05-23 Downgrade UBS
Buy → Neutral
$20 → $16
Dec-14-22 Initiated Deutsche Bank
Buy
$25
Dec-07-22 Initiated RBC Capital Mkts
Outperform
$22
Nov-03-22 Downgrade BofA Securities
Buy → Neutral
$32 → $17
Aug-25-22 Initiated Credit Suisse
Outperform
$34
Aug-05-21 Resumed Credit Suisse
Outperform
$44
Dec-16-20 Initiated KeyBanc Capital Markets
Overweight
$33
Dec-15-20 Initiated William Blair
Outperform
Dec-15-20 Initiated Stifel
Buy
$31
Dec-15-20 Initiated Robert W. Baird
Outperform
$31
Dec-15-20 Initiated Jefferies
Buy
Dec-15-20 Initiated Goldman
Buy
$38
Dec-15-20 Initiated Credit Suisse
Outperform
Show Previous Ratings
Aug-28-24 07:49AM
Aug-12-24 08:05AM
Aug-08-24 12:45AM
Aug-07-24 04:05PM
Jul-29-24 04:05PM
08:00AM
Loading…
Jul-10-24 08:00AM
Jul-02-24 04:00PM
Jun-20-24 09:15AM
Jun-17-24 09:54AM
Jun-12-24 02:38AM
May-17-24 11:52AM
May-13-24 08:00AM
May-09-24 04:18PM
(Insider Monkey) +11.16%
+6.09%
04:05PM
10:53AM
10:11AM
Loading…
10:11AM
04:02AM
03:15AM
May-08-24 08:57PM
04:05PM
Apr-30-24 07:31AM
Apr-18-24 07:36AM
Apr-10-24 04:05PM
Mar-28-24 04:00PM
Mar-19-24 07:48AM
Mar-12-24 04:15PM
Feb-23-24 12:15PM
10:10AM
(Thomson Reuters StreetEvents)
Feb-22-24 08:30PM
04:43PM
04:05PM
Loading…
04:05PM
Feb-21-24 08:00AM
Feb-13-24 08:30AM
Feb-11-24 05:00PM
Feb-07-24 06:46AM
Jan-29-24 08:00AM
Dec-18-23 05:27AM
Nov-24-23 08:39AM
Nov-09-23 08:15AM
Nov-08-23 04:02PM
12:00AM
Nov-07-23 04:49PM
04:05PM
Nov-02-23 06:47AM
Oct-20-23 12:08PM
Oct-17-23 08:15AM
Sep-29-23 12:43PM
08:15AM
Sep-25-23 08:49AM
Sep-19-23 09:31AM
Sep-05-23 04:15PM
Aug-23-23 08:15AM
Aug-22-23 08:14AM
Aug-09-23 04:15PM
06:03AM
Aug-08-23 06:20AM
01:30AM
Aug-07-23 04:05PM
Jul-27-23 04:05PM
Jul-24-23 04:05PM
Jul-20-23 04:05PM
Jul-18-23 08:37AM
Jul-16-23 08:51AM
Jun-06-23 08:00AM
May-24-23 08:10AM
May-09-23 12:49PM
(Thomson Reuters StreetEvents) -13.02%
08:00AM
01:00AM
May-08-23 05:35PM
04:05PM
Apr-17-23 04:15PM
Mar-28-23 05:00PM
Mar-20-23 06:50AM
Mar-13-23 08:45AM
Mar-09-23 06:40AM
Mar-08-23 08:00AM
Mar-04-23 08:19AM
Mar-02-23 08:45AM
Feb-27-23 05:35AM
Feb-23-23 01:00AM
Feb-22-23 05:55PM
04:05PM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-14-23 04:33PM
Feb-07-23 10:15AM
Feb-06-23 07:34AM
Feb-01-23 08:00AM
Jan-27-23 09:37AM
Jan-16-23 08:30AM
Dec-12-22 09:53AM
Dec-01-22 04:01PM
Nov-28-22 08:30AM
Nov-16-22 05:05PM
Nov-09-22 07:16AM
Nov-07-22 04:10PM
Nov-06-22 07:30AM
Nov-03-22 04:05PM
(GlobeNewswire) -5.53%
+6.89%
12:30AM
Nov-02-22 06:15PM
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers' research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GTCR INVESTMENT XI LLC Director May 28 '24 Sale 9.81 9,940,974 97,570,660 20,150,005 May 30 05:39 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
